Buchwald A, Hochhaus G
Department of Pharmaceutics, Health Science Center, University of Florida, Gainesville 32610-0497, USA.
Int J Clin Pharmacol Ther. 1998 Dec;36(12):652-60.
Salmeterol xinafoate is a highly selective beta2-adrenoceptor for the maintenance treatment of asthma in adults and children.
To review the pharmacokinetics, clinical pharmacology, and therapeutic properties of a recently introduced, long acting antiasthmatic drug.
Recent English-language publications were selected using Medline as database.
Salmeterol's pharmacokinetics, clinical pharmacology, and therapeutic properties are reviewed and aspects related to salmeterol's unusual duration of action, its high potency, beta2-selectivity, possible antiinflammatory actions, its interaction with other drugs, low systemic adverse effects, dosage, and administration are also discussed.
Salmeterol is a safe long-acting beta2-agonist very useful for maintenance treatment of asthma.
